ACA Pharma

Acacia Pharma is a hospital-focused pharmaceutical company dedicated to developing and commercializing novel treatments for patients undergoing surgical and medical procedures. The company’s portfolio is led by Barhemsys (amisulpride), an intravenous dopamine antagonist approved for both the treatment and prophylaxis of postoperative nausea and vomiting (PONV). Acacia also commercializes Byfavo (remimazolam), a rapid-onset, ultra-short-acting sedative for adult patients undergoing procedural sedation. Beyond its commercial assets, the company has explored the use of amisulpride for chemotherapy-induced nausea and vomiting (CINV). In June 2022, Acacia Pharma was acquired by Eagle Pharmaceuticals, which aimed to leverage Acacia’s commercial infrastructure and hospital-based products. The company was founded in 2007 and maintained key operations in the United Kingdom and the United States prior to its acquisition.